Hesketh PJ - Search Results

1

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches.

Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D. Hesketh PJ, et al. Support Care Cancer. 2004 Aug;12(8):543-9. doi: 10.1007/s00520-003-0562-5. Epub 2004 Jun 19. Support Care Cancer. 2004. PMID: 15221580 Review.

2

New treatment options for chemotherapy-induced nausea and vomiting.

Hesketh PJ. Hesketh PJ. Support Care Cancer. 2004 Aug;12(8):550-4. doi: 10.1007/s00520-004-0651-0. Epub 2004 Jun 30. Support Care Cancer. 2004. PMID: 15232725 Review.

3

Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.

Hesketh PJ. Hesketh PJ. Support Care Cancer. 1994 Sep;2(5):286-92. doi: 10.1007/BF00365579. Support Care Cancer. 1994. PMID: 8000724 Review.

4

Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting.

Hesketh PJ. Hesketh PJ. Support Care Cancer. 2001 Jul;9(5):350-4. doi: 10.1007/s005200000199. Support Care Cancer. 2001. PMID: 11497388 Review.

5

Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity.

Hesketh PJ, Gralla RJ, du Bois A, Tonato M. Hesketh PJ, et al. Support Care Cancer. 1998 May;6(3):221-7. doi: 10.1007/s005200050157. Support Care Cancer. 1998. PMID: 9629873 Review.

6

Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.

Hesketh PJ, Gandara DR, Hesketh AM, Facada A, Perez EA, Webber LM, Martin LA, Cramer MB, Hahne WF. Hesketh PJ, et al. Among authors: hesketh am. Support Care Cancer. 1996 Mar;4(2):141-6. doi: 10.1007/BF01845763. Support Care Cancer. 1996. PMID: 8673351 Clinical Trial.

7

Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen.

Hesketh PJ, Roman A, Hesketh AM, Perez EA, Edelman M, Gandara DR. Hesketh PJ, et al. Among authors: hesketh am. Support Care Cancer. 2000 Jan;8(1):46-8. doi: 10.1007/s005209900077. Support Care Cancer. 2000. PMID: 10650897 Clinical Trial.

8

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.

Hesketh PJ, Grunberg SM, Herrstedt J, de Wit R, Gralla RJ, Carides AD, Taylor A, Evans JK, Horgan KJ. Hesketh PJ, et al. Support Care Cancer. 2006 Apr;14(4):354-60. doi: 10.1007/s00520-005-0914-4. Epub 2006 Feb 1. Support Care Cancer. 2006. PMID: 16450086 Clinical Trial.

9

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy.

Hesketh PJ, Aapro M, Street JC, Carides AD. Hesketh PJ, et al. Support Care Cancer. 2010 Sep;18(9):1171-7. doi: 10.1007/s00520-009-0737-9. Epub 2009 Sep 12. Support Care Cancer. 2010. PMID: 19756774 Clinical Trial.

10

Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC).

Hesketh PJ, Morrow G, Komorowski AW, Ahmed R, Cox D. Hesketh PJ, et al. Support Care Cancer. 2012 Oct;20(10):2633-7. doi: 10.1007/s00520-012-1527-3. Epub 2012 Jun 24. Support Care Cancer. 2012. PMID: 22733373 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

193 results

Search Page